Meeting News

Rapidly expanding treatment options improving survival in acute myeloid leukemia

April 17, 2019
ORLANDO — Treatment options in acute myeloid leukemia are changing rapidly and improving OS of young and elderly patients, according to a…

Trial to assess novel targeted therapy for rare form of kidney cancer

April 15, 2019
A preclinical study that yielded new insights into a rare pediatric malignancy laid the foundation for a phase 2 trial that is evaluating a novel…

Phase 0 trials ‘quickest route’ for development of glioblastoma treatments

April 10, 2019
Ivy Brain Tumor Center at The Barrow Neurological Institute has launched a program that offers phase 0 trials to accelerate the drug approval process…
Molecular Oncology

Treatment response in AML: Understanding available molecular diagnostic data

HemOnc Today, April 10, 2019
David F. Claxton, MD; Megan Wheelden, MD
“Doctor, am I in remission?” The honest current answer is often: “It depends what you mean by remission.”

Immunotherapy for head and neck cancer an evolving paradigm

HemOnc Today, April 10, 2019
Charu Aggarwal, MD, MPH
The availability and approval of checkpoint inhibitors has transformed the management of metastatic head and neck squamous cell carcinoma. In 2016…

Is ibrutinib-based therapy the preferred initial treatment for all patients with CLL?

HemOnc Today, April 10, 2019
POINT CLL is the most common leukemia among adults. Standard treatment is combination chemoimmunotherapy with regimens such as chlorambucil plus…
Cover Story

Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’

HemOnc Today, April 10, 2019
The transition from primarily chemotherapy-based approaches to targeted therapies revolutionized treatment of chronic lymphocytic leukemia, the most…

BRCA Exchange addresses ‘urgent need’ for data sharing in cancer predisposition research

April 9, 2019
The Global Alliance for Genomics and Health has launched a global public repository that includes data on thousands of inherited variants in the…

Trial explores T-cell therapy’s role in personalized treatment for lung cancer

April 4, 2019
ATLANTA — In the battle against non-small cell lung cancer, the ability to personalize treatment may be a key to victory, according to Karen

Will CAR T cells become first-line therapy for hematologic malignancies?

HemOnc Today, March 25, 2019
POINT CAR T cells have already changed the treatment paradigm for recurrent and resistant DLBCL, which, as shown in the SCHOLAR-I study, has a dismal…